We are live on
!
Find out more
ANI Pharmaceuticals
ANIP
ANIP
117 hedge funds and large institutions have $239M invested in ANI Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 48 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
1% more funds holding
Funds holding: 116 → 117 (+1)
0.44% more ownership
Funds ownership: 56.66% → 57.11% (+0.44%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $252M → $239M (-$13.7M)
44% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 48
45% less call options, than puts
Call options by funds: $560K | Put options by funds: $1.01M
Holders
117
Holders Change
+1
Holders Change %
+0.86%
% of All Funds
2.05%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
27
Reduced
48
Closed
12
Calls
$560K
Puts
$1.01M
Net Calls
-$454K
Net Calls Change
+$107K
Top Buyers
Top Sellers
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.9M |
| 2 |
Goldman Sachs
New York
|
-$1.57M |
| 3 |
Charles Schwab
San Francisco,
California
|
-$1.39M |
| 4 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
-$1.29M |
| 5 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
-$1.07M |
